Elsevier

Neurologic Clinics

Volume 29, Issue 2, May 2011, Pages 435-448
Neurologic Clinics

Promising Emerging Therapies for Multiple Sclerosis

https://doi.org/10.1016/j.ncl.2011.01.003Get rights and content

Section snippets

Potential targets for treating multiple sclerosis

Targets for treating MS include immune dysfunction (anti–T- and anti–B-cell therapies), immune regulation (enhancing T-regulatory function), reducing permeability of BBB, preventing transmigration of cells across the BBB (antiadhesion molecule therapies), targeting key mediators of the inflammatory cascade (anticytokine therapies), putative autoantigens (immune tolerance), reducing demyelination, preventing neuroaxonal loss (neuroprotection), promoting remyelination, and augmenting regenerative

Anti-CD52 (Alemtuzumab [Campath-1H])

Alemtuzumab (Genzyme and Bayer Schering) is currently in late phase III development. Alemtuzumab is a humanized IgG1 mAb that binds to CD52 on leukocytes. It rapidly depletes CD52-bearing leukocytes, which include T cells, B cells, NK cells, monocytes and macrophages, and some granulocytes.20 Whether or not it functions by depleting autoreactive cells directly involved in the autoaggressive cascade is a moot point. Other actions of alemtuzumab include stabilization the BBB and possible

Oral agents

Current first-line DMTs are administered as subcutaneous or intramuscular (IM) injections and are associated with frequent side effects, including injection site reactions, flu-like symptoms, and lipoatrophy, although the more effective natalizumab and the mAbs (discussed previously) require regular parenteral administration and come with potential life-threatening side effects and/or undefined long-term risks. Therefore, the holy grail of MS has been to develop oral agents that are at least as

Summary

Not all patients respond to interferon beta and glatiramer acetate treatment. For suboptimal or nonresponders, current options include switching between classes or escalating therapy to natalizumab or mitoxantrone. The recent licensing of cladribine and fingolimod in some countries expands the options of treatment for patients who are treatment-naïve and those who are failing parenteral therapies because of lack of efficacy, poor tolerance, or unacceptable risks (eg, PML on natalizumab). The

First page preview

First page preview
Click to open first page preview

References (77)

  • L. Kappos et al.

    Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

    Lancet

    (2008)
  • D.A. Carson et al.

    Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes

    Blood

    (1983)
  • E. Beutler et al.

    Treatment of multiple sclerosis and other autoimmune diseases with cladribine

    Semin Hematol

    (1996)
  • C. Brunmark et al.

    The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis

    J Neuroimmunol

    (2002)
  • J.S. Yang et al.

    Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats

    J Neuroimmunol

    (2004)
  • G. Comi et al.

    Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

    Lancet

    (2008)
  • L. Steinman

    Multiple sclerosis. Presenting an odd autoantigen

    Nature

    (1995)
  • C. Stadelmann et al.

    Cortical pathology in multiple sclerosis

    Curr Opin Neurol

    (2008)
  • G. Giovannoni et al.

    Multiple sclerosis: the environment and causation

    Curr Opin Neurol

    (2007)
  • L. Steinman et al.

    How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis

    Ann Neurol

    (2006)
  • M. Sospedra et al.

    Immunology of multiple sclerosis

    Annu Rev Immunol

    (2005)
  • M. Jacobsen et al.

    Oligoclonal expansion of memory CD8+ T cells in cerebrospinal fluid from multiple sclerosis patients

    Brain

    (2002)
  • R. Hohlfeld et al.

    Dual role of inflammation in CNS disease

    Neurology

    (2007)
  • E.P. Bowman et al.

    Rationale and safety of anti-interleukin-23 and anti-interleukin-17A therapy

    Curr Opin Infect Dis

    (2006)
  • B.D. Trapp et al.

    Axonal transection in the lesions of multiple sclerosis

    N Engl J Med

    (1998)
  • B. Ferguson et al.

    Axonal damage in acute multiple sclerosis lesions

    Brain

    (1997)
  • L.M. Sayre et al.

    Oxidative stress and neurotoxicity

    Chem Res Toxicol

    (2008)
  • S.G. Waxman

    Axonal conduction and injury in multiple sclerosis: the role of sodium channels

    Nat Rev Neurosci

    (2006)
  • B. Hemmer et al.

    Pathogenesis of multiple sclerosis: an update on immunology

    Curr Opin Neurol

    (2002)
  • R.J. Franklin et al.

    Remyelination in the CNS: from biology to therapy

    Nat Rev Neurosci

    (2008)
  • A.J. Coles et al.

    Dehydroepiandrosterone replacement in patients with Addison’s disease has a bimodal effect on regulatory (CD4+CD25hi and CD4+FoxP3+) T cells

    Eur J Immunol

    (2005)
  • S.A. Thompson et al.

    B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis

    J Clin Immunol

    (2010)
  • A.J. Coles et al.

    The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy

    J Neurol

    (2006)
  • A.J. Coles et al.

    Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

    N Engl J Med

    (2008)
  • A.J. Coles et al.

    Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

    N Engl J Med

    (2008)
  • M.R. Clatworthy et al.

    Anti-glomerular basement membrane disease after alemtuzumab

    N Engl J Med

    (2008)
  • A.P. Jillella et al.

    Autoimmune thrombocytopenia following autologous hematopoietic cell transplantation: review of literature and treatment options

    Bone Marrow Transplant

    (2000)
  • J.L. Jones et al.

    IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)

    J Clin Invest

    (2009)
  • Cited by (0)

    Disclosures: Professor Giovannoni has received consulting fees from Bayer Schering Healthcare, Biogen-Idec, FivePrime Therapeutics, Genzyme, GlaxoSmithKline, GW Pharma, Ironwood Pharmaceuticals, Merck-Serono, Novartis, Protein Discovery Laboratories, Roche, Teva-Aventis, Vertex Pharmaceuticals, and UCB Pharma; lecture fees from Bayer Schering Healthcare, Biogen-Idec, Pfizer, Teva-Aventis, and Vertex Pharmaceuticals; and grant support from Bayer Schering Healthcare, Biogen-Idec, GW Pharma, Merck-Serono, Merz, Novartis, Teva-Aventis, and UCB Pharma.

    View full text